在哮喘患者中高剂量和低剂量吸入瑞米特罗与沙丁胺醇的比较。

A comparison of rimiterol and salbutamol by inhalation at high and low dose in asthmatic patients.

作者信息

Muittari A

出版信息

Respiration. 1978;35(3):165-72. doi: 10.1159/000193873.

DOI:10.1159/000193873

Abstract

Rimiterol hydrobromide (Pulmadil) has been shown to have a dose-related bronchodilator effect; the optimum dose by inhalation appears to lie between 200 and 1,000 microgram. When given to a group of asthmatic patients at 'recommended' and 5--10 times 'recommended' dose by aerosol, cardiovascular effects were minimal and of a magnitude similar to that of salbutamol given in the same dosages to the same patients. The very rapid bronchodilator effect of rimiterol would appear to make the drug particularly suitable for the treatment of patients with intermittent asthmatic attacks, before exercise in patients with exercise-induced asthma and for bronchodilatation before using inhaled sodium cromoglycate or corticosteroid aerosols.

摘要

氢溴酸瑞米特罗（喘速平）已被证明具有剂量相关的支气管扩张作用；吸入的最佳剂量似乎在200至1000微克之间。当以“推荐”剂量和气溶胶形式给予一组哮喘患者5至10倍“推荐”剂量时，心血管效应极小，其程度与以相同剂量给予同一患者的沙丁胺醇相似。瑞米特罗极快的支气管扩张作用似乎使该药特别适用于治疗间歇性哮喘发作的患者、运动诱发性哮喘患者运动前的治疗以及在使用吸入性色甘酸钠或皮质类固醇气雾剂前进行支气管扩张。